Novonesis Inkomsten in het verleden

We zijn nog bezig met het verwerken van het laatste winstrapport van dit bedrijf

Verleden criteriumcontroles 0/6

De winst van Novonesis is gedaald met een gemiddeld jaarlijks percentage van -1.3%, terwijl de winst van de Chemicals -industrie jaarlijks groeide met 7.2%. De inkomsten zijn groeide met een gemiddeld percentage van 8.1% per jaar. Het rendement op het eigen vermogen Novonesis bedraagt 2.6% en de nettomarge bedraagt 9.3%.

Belangrijke informatie

-1.3%

Groei van de winst

-0.6%

Groei van de winst per aandeel

Chemicals Groei van de industrie	13.1%
Inkomstengroei	8.1%
Rendement op eigen vermogen	2.6%
Nettomarge	9.3%
Volgende winstupdate	26 Feb 2025

Recente prestatie-updates uit het verleden

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Opbrengsten en kosten

Hoe Novonesis geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

CPSE:NSIS B Opbrengsten, kosten en inkomsten (EUR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	3,045	283	575	326
31 Mar 24	2,696	332	506	298
31 Dec 23	2,401	406	446	271
30 Sep 23	2,390	430	441	270
30 Jun 23	2,382	460	446	272
31 Mar 23	2,390	487	441	270
31 Dec 22	2,360	494	430	267
30 Sep 22	2,268	460	443	262
30 Jun 22	2,186	418	418	257
31 Mar 22	2,090	416	403	257
31 Dec 21	2,009	423	380	266
30 Sep 21	1,958	427	335	268
30 Jun 21	1,914	409	322	274
31 Mar 21	1,883	389	310	270
31 Dec 20	1,883	380	309	256
30 Sep 20	1,920	415	309	248
30 Jun 20	1,955	405	326	254
31 Mar 20	1,968	439	335	264
31 Dec 19	1,924	422	329	263
30 Sep 19	1,923	411	334	262
30 Jun 19	1,917	434	321	260
31 Mar 19	1,922	417	315	249
31 Dec 18	1,927	432	313	248
30 Sep 18	1,924	427	311	254
30 Jun 18	1,915	429	310	247
31 Mar 18	1,920	423	320	248
31 Dec 17	1,952	419	332	255
30 Sep 17	1,958	421	334	255
30 Jun 17	1,934	412	332	254
31 Mar 17	1,919	414	328	251
31 Dec 16	1,902	410	325	251
30 Sep 16	1,864	394	327	247
30 Jun 16	1,883	394	333	253
31 Mar 16	1,883	384	331	259
31 Dec 15	1,876	378	330	254
30 Sep 15	1,840	366	320	255
30 Jun 15	1,795	353	314	252
31 Mar 15	1,741	340	311	243
31 Dec 14	1,673	339	306	237
30 Sep 14	1,641	334	314	227
30 Jun 14	1,605	324	310	216
31 Mar 14	1,598	319	312	211
31 Dec 13	1,575	295	311	205

Kwaliteitswinsten: NSIS B heeft een grote eenmalige verlies van €105.1M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2024.

Groeiende winstmarge: De huidige netto winstmarges (9.3%) NSIS B } zijn lager dan vorig jaar (19.3%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van NSIS B is de afgelopen 5 jaar met 1.3% per jaar gedaald.

Versnelling van de groei: De winstgroei NSIS B is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: NSIS B had het afgelopen jaar een negatieve winstgroei ( -38.5% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Chemicals ( -6.3% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 2.6% ) van NSIS B wordt als laag beschouwd.

Novonesis Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings: Revenues in line with analyst expectations

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Third quarter 2023 earnings: Revenues exceed analyst expectations

Recent updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022